Efficacy and Safety of Neoadjuvant Chemoradiotherapy Plus Apatinib for Patients with Locally Advanced, HER2-negative, Siewert's Type II-III Adenocarcinoma of Esophagogastric Junction: a Single-Arm, Open-Label, Phase II Trial.
American Journal of Translational Research（2021）
Key words
Neoadjuvant chemoradiotherapy,apatinib,adenocarcinoma of esophagogastric junction,efficacy,safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined